The Log
Archive
733 stories, newest first.
June 2026
- Jun 6Treatment & Recovery
In Four States, Doctors Can Get Paid to Treat Meth Addiction. In Arizona, There Is No Treatment.
Four states now cover contingency management under Medicaid for stimulant use disorder. Arizona is not one of them. With no FDA-approved medications for meth and overdose deaths rising 17% in AZ, the treatment gap is lethal.
- Jun 6Science & Medicine
At the Clinical Threshold: MDMA Has a VA Trial, Ibogaine Has 71% Abstinence Data, and Psilocybin Has Two States. Insurance Has None of This.
The VA launched an MDMA trial for PTSD and alcohol use disorder in veterans on June 2, 2026. Stanford's ibogaine study shows 71% abstinence in treatment-resistant OUD. Compass Pathways may have FDA approval by early 2027. The access question hasn't been answered.
- Jun 6Harm Reduction
The April Memo That Ended the Test Strip Era
On April 24, 2026, SAMHSA banned federal funding for fentanyl test strips, syringes, and other harm reduction supplies. Ohio ran out of strips by June 5. Phoenix banned park distribution June 1. Arizona overdoses are up 20% against a national decline.
- Jun 5Lived Experience & Community
Recovery Is Their Credential. It's Also Their Vulnerability.
New qualitative research names the 'wounded healer' paradox in peer support work: the recovery credential that gets you hired is the same thing that makes the job uniquely dangerous for your own sobriety.
- Jun 5Technology & Innovation
An AI Can Now Diagnose Addiction With 83% Accuracy. The Treatment System Still Can't Keep Up.
University of Cincinnati researchers built an AI that diagnoses substance use disorder with 83% accuracy using behavioral economics tools. The harder problem is what happens after the diagnosis.
- Jun 5Science & Medicine
GLP-1 Drugs Slashed Overdose Deaths by 50% in a New BMJ Study. Here's What It Actually Means.
A June 2026 BMJ study found GLP-1 medications reduced drug-related deaths by 50% and overdoses by 40% in people with existing substance use disorders. The findings could reshape how we think about addiction pharmacotherapy.
- Jun 5Science & Medicine
What Ketamine Does to Your Brain — and Why Regulators Can't Agree on What to Do About It
Ketamine works in hours when antidepressants take weeks. A March 2026 study in Molecular Psychiatry finally explains why — and also why the regulatory chaos surrounding it is far from over.
- Jun 5Policy & Funding
The Exemption That Isn't
CMS finalized Medicaid work requirements on June 1, 2026. The SUD exemption sounds protective — but its fine print narrows eligibility in ways that could strip coverage from 1.6 million people in treatment.
- Jun 4Treatment & Recovery
California's Contingency Management Program Just Hit 10,000 Patients. Forty-Five States Don't Have One.
California's Recovery Incentives Program hit ~10,000 patients. Five states have CMS-approved Medicaid contingency management programs. The other 45 — including Arizona — are leaving the most evidence-based stimulant treatment on the table.
- Jun 4The Crisis, By the Numbers
Overdose Deaths Fell 14 Percent in 2025. The Decline Is Already Slowing.
CDC provisional data shows 69,973 drug overdose deaths in 2025 — a 14% decline from 2024 and the largest single-year drop in recorded history. The rate of decline is already slowing. The programs being cut right now drove the improvement.
- Jun 4Science & Medicine
Cannabis Has Been Legal in Thirty-Eight States. There Is Still No FDA-Approved Treatment for Cannabis Use Disorder.
The DEA's June 29 hearing on broader marijuana rescheduling could unlock research infrastructure for cannabis use disorder — currently the only major SUD with zero FDA-approved medications. 19.2 million Americans have CUD. The treatment gap is enormous.
- Jun 4Policy & Funding
The Rule That Looks Like a Win Has a Trap in It
The CMS Interim Final Rule finalized June 1 exempts people with SUD from Medicaid work requirements — but only until they've been in recovery for five years. Here's what that cliff means for 1.6 million enrollees and for Arizona specifically.
- Jun 3The Crisis, By the Numbers
Overdose Deaths Fell Everywhere. Cocaine Didn't Get the Memo.
Stimulant-only overdose deaths rose to 23.8% of all U.S. drug fatalities in 2024, even as overall deaths fell 24%. Cocaine deaths disproportionately kill Black Americans. There is no FDA-approved medication for cocaine use disorder.
- Jun 3Arizona Watch
Arizona Spent $582 Million on SUD Treatment Last Year. Federal Policy Is About to Test Whether That Investment Survives.
AHCCCS spent $582 million on SUD treatment in FY2025, with Medicaid as the primary payer. The new federal work requirements, going live by December 31, 2026, don't cut the treatment funding — they cut the coverage that pays for it.
- Jun 3Science & Medicine
Prescribed and Trapped: Medicare's Benzodiazepine Numbers Reveal a Crisis Built by Doctors
A 2026 Frontiers in Medicine study found Medicare benzodiazepine prescribing rose 51% from 2017–2023 — even as overall U.S. prescribing fell 26%. Seniors average 108 days of medication per year against a 30-day guideline.
- Jun 3The Crisis, By the Numbers
The Overdose Decline Is Real. The People Still Dying Are Increasingly Black, Indigenous, and Killed by Stimulants.
Friedman et al. in Addiction (June 2, 2026): overdose deaths fell 24.4% in 2024 — the first-ever decline across all four waves of the crisis. But stimulant-only deaths rose to 23.8% of all fatalities, concentrated in Black and Indigenous communities.
- Jun 3Policy & Funding
Eighty Hours a Month. Prove It or Lose Medicaid. For People With Addiction, the Exemption That Looks Like a Solution Isn't.
CMS finalized Medicaid work requirements on June 2, 2026. The SUD treatment exemption exists on paper — but implementation dynamics identical to Arkansas 2018, where 18,000 lost coverage, are set to repeat nationally by December 31.
- Jun 2Lived Experience & Community
The Peer Recovery Workers Who Got Their Grants Back — and Still Don't Know If They'll Have a Job in September
SAMHSA reversed its January 2026 grant terminations within 24 hours. Peer recovery support workers got their funding back — on paper. What's still missing is any certainty it will last.
- Jun 2Science & Medicine
The FDA Fast-Tracked Three Psychedelic Drugs. That's Not the Same as Approving Them.
FDA priority vouchers went to three psychedelic companies in April 2026. Here's what a priority voucher does, what it doesn't do, and where psilocybin and methylone actually stand on the path to approval.
- Jun 2Treatment & Recovery
Five States Are Now Paying People to Stay Sober. It's Working.
Five states now offer contingency management as a Medicaid benefit, targeting stimulant use disorder. For a condition with no FDA-approved medications, it's the strongest evidence-based tool available — and it remains unavailable in most of the country.
- Jun 2Science & Medicine
The Medication That Could Help 14.5 Million People — and That Fewer Than 5% of Them Ever Receive
Naltrexone was FDA-approved for alcohol use disorder in 1994. Fewer than 3% of primary care physicians prescribe it for AUD. An honest look at why — and what the craving science says about how the medication works.
- Jun 2Science & Medicine
Ozempic for Alcohol: What the May 2026 Lancet Trial Actually Proves
The May 2026 Lancet trial of semaglutide for alcohol use disorder showed significant reductions in heavy drinking days and cravings. A breakdown of the findings, the limitations, and what comes next for AUD pharmacotherapy.
- Jun 2Policy & Funding
The Line Items They'd Kill Are the Ones Funding the Human Work
The proposed Behavioral Health Innovation Block Grant cuts $813M in categorical grants that paid for syringe programs, peer recovery workers, overdose data, and workforce development. A guide to what actually gets eliminated — and why the 5% headline number misses the point.
- Jun 1Arizona Watch
Maricopa County Is Starting Medications in Jail. That’s the Point.
Maricopa County's $4.3M opioid settlement disbursement includes targeted investment in MOUD initiation inside county jails — starting buprenorphine or methadone before release, with a warm handoff to a community prescriber.